SpyGlass Pharma, Inc. (SGP)

SpyGlass Pharma Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2024	Dec 31, 2023
Net Income	-35.71	-29.16	-13.32
Depreciation & Amortization	0.5	0.27	0.12
Share-Based Compensation	-	1.49	0.87
Other Operating Activities	5.59	5.38	0.04
Operating Cash Flow	-29.62	-22.03	-12.28
Capital Expenditures	-0.81	-1.99	-0.22
Change in Investments	-	24.25	-20.27
Investing Cash Flow	-8.33	22.26	-20.49
Share Issuance / Repurchase	-	0.18	39.77
Financing Cash Flow	125.62	0.18	39.77
Net Cash Flow	87.67	0.42	7.01
Free Cash Flow	-30.42	-24.02	-12.49

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).